

Trinity Health Grand Haven Hospital
Cumulative Antimicrobial Susceptibility Summary Jan. 1, 2025 - Dec. 31, 2025
BioMerieux Vitek® 2 MIC Methodology

NON-URINE SOURCE

Organism	%Susceptible																										
	# Isolates	Ampicillin	Amp/ Sulbactam	Cefazolin	Cefepime	Ceftazidime	Ceftriaxone	Ciprofloxacin	Clindamycin	Daptomycin	Doxycycline	Ertapenem	Erythromycin	Gentamicin	Gentamicin(high level)	Levofloxacin	Linezolid	Meropenem	Moxifloxacin	Oxacillin	Pip/Tazobactam	Rifampicin	Streptomycin(high level)	Tetracycline	Tigecycline	T/S	Vancomycin
Coagulase Negative Staph	21 ¹	*	*	*	*	*	*	90	48	100	90	*	43	95	*	90	100	*	100	52	*	100	*	90	100	76	100
Enterococcus faecalis	34	100	*	*	*	*	*	88	*	71	24	*	12	*	91	88	100	*	*	*	*	*	94	24	100	*	100
Escherichia coli	54	63	70	70	100	98	96	85	*	*	*	100	*	96	*	85	*	100	*	96	*	*	*	*	*	74	*
Pseudomonas aeruginosa	30	*	*	*	100	100	*	86	*	*	*	*	*	97	*	86	*	100	*	*	100	*	*	*	*	*	*
Staphylococcus aureus	103	*	*	*	*	*	*	78	80	100	98	*	57	100	*	80	100	*	93	76	*	100	*	92	100	94	100
Methicillin Resistant Staph aureus	24 ¹	*	*	*	*	*	*	42	83	100	96	*	21	100	*	42	100	*	83	0	*	100	*	92	100	83	100
Methicillin Susceptible Staph aureus	79	*	*	*	*	*	*	89	78	100	99	*	68	100	*	91	100	*	96	100	*	100	*	92	100	97	100
Staphylococcus lugdunensis	4 ¹	*	*	*	*	*	*	100	100	100	100	*	100	100	*	100	100	*	100	100	*	100	*	100	100	100	100

URINE SOURCE

URINE SOURCE	%Susceptible																											
	Organism	# Isolates	Ampicillin	Amp/Sulbactam	Cefazolin	Cefepime	Ceftazidime	Ceftriaxone	Ciprofloxacin	Daptomycin	Doxycycline	Ertapenem	Gentamicin	Gentamicin(high level)	Levofloxacin	Linezolid	Meropenem	Moxifloxacin	Nitrofurantoin	Oxacillin	Pi p/Tazobactam	Rifampicin	Streptomycin(high level)	Tetracycline	Tigecycline	T/S	Vancomycin	
Coagulase negative staph	61	*	*	*	*	*	*	79	100	92	*	100	*	80	100	*	87	98	30	*	100	*	85	100	77	100		
Enterococcus faecalis	95	100	*	*	*	*	*	82	72	31	*	*	86	84	95	*	*	100	*	*	*	90	22	100	*	98		
Escherichia coli	765	100	76	94	97	96	96	91	*	*	100	93	*	91	*	100	*	98	*	98	*	*	*	*	83	*		
ESBL-producing E Coli	20 ¹	0	35	5	35	35	5	25	*	*	100	75	*	25	*	100	*	84	*	81	*	*	*	*	58	*		
Klebsiella oxytoca	25 ¹	0	64	*	96	96	92	100	*	*	100	100	*	100	*	100	*	95	*	75	*	*	*	*	45	*		
Klebsiella pneumoniae	126	0	89	*	95	93	93	95	*	*	99	98	*	95	*	100	*	25	*	98	*	*	*	*	90	*		
Proteus mirabilis	71	89	94	96	97	100	97	66	*	*	100	96	*	68	*	100	*	0	*	100	*	*	*	*	76	*		
Pseudomonas aeruginosa	61	*	*	*	98	97	*	90	*	*	*	97	*	89	*	98	*	*	*	98	*	*	*	*	*	*		
Staphylococcus aureus	23 ¹	*	*	*	*	*	*	61	100	87	*	96	*	61	100	*	83	100	52	*	100	*	87	100	100	100		
Methicillin Resistant Staph aureus	11 ¹	*	*	*	*	*	*	27	100	73	*	91	*	27	100	*	64	100	0	*	100	*	73	100	100	100		
Methicillin Susceptible Staph aureus	12 ¹	*	*	*	*	*	*	92	100	100	*	100	*	92	100	*	100	100	100	*	100	*	100	100	100	100		
Staphylococcus lugdunensis	6 ¹	*	*	*	*	*	*	100	100	100	*	100	*	100	100	*	100	100	50	*	100	*	100	100	100	100		

*Drug not tested or drug not indicated

¹less than desirable # of isolates for statistical validity, ≥30 isolates is considered clinically significant

Trinity Health Grand Haven Hospital
Cumulative Antimicrobial Susceptibility Summary Jan. 1, 2024 - Dec. 31, 2024
BioMerieux Vitek® 2 MIC Methodology

NON-URINE SOURCE

Organism	%Susceptible															
	# Isolates	Aminicacin	Ampicillin/Clavulanic Acid	Aztreonam	Cefotaxime	Cefepime	Ceftazidime/Avibactam	Ceftazidime/Tazobactam	Doxycycline	Erythromycin	Imipenem	Meropenem/Vaborbactam	Moxifloxacin	Polymyxin B	Tigecycline	Tobramycin
<i>Escherichia coli</i>	37	100	89	100	95	95	100	100	81	100	100	100	89	*	100	100

URINE SOURCE

Organism	%Susceptible															
	# Isolates	Aminicacin	Ampicillin/Clavulanic Acid	Aztreonam	Cefotaxime	Cefepime	Ceftazidime/Avibactam	Ceftazidime/Tazobactam	Doxycycline	Erythromycin	Imipenem	Meropenem/Vaborbactam	Moxifloxacin	Polymyxin B	Tigecycline	Tobramycin
<i>Escherichia coli</i>	69	100	80	99	94	91	100	100	91	100	100	100	97	*	100	94
<i>ESBL-producing E Coli</i>	4 ¹	100	25	75	0	0	100	100	75	100	100	100	100	*	100	25
<i>Klebsiella pneumoniae</i>	20 ¹	100	90	90	90	90	100	100	80	100	100	100	95	*	95	95

*Drug not tested or drug not indicated

¹less than desirable # of isolates for statistical validity, ≥30 isolates is considered clinically significant